Home >> Signaling Pathways >> TGF-β / Smad Signaling >> Bcr-Abl

Bcr-Abl(Bcr-Abl酪氨酸激酶)

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

  1. Cat.No. 产品名称 Information
  2. GC25669 Nilotinib hydrochloride Nilotinib hydrochloride (AMN-107) is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
  3. GC65592 SNIPER(ABL)-020
  4. GC64462 Asciminib hydrochloride An allosteric inhibitor of Abl1
  5. GC63332 S116836
  6. GC62453 GZD856 formic
  7. GC62207 Olverembatinib A Bcr/Abl inhibitor
  8. GC62103 Vodobatinib Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively.
  9. GC60930 Imatinib D4
  10. GC39612 Imatinib D8
  11. GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib
  12. GC36807 ON 146040
  13. GC36167 GMB-475 GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.
  14. GC35897 DPH
  15. GC35812 Dasatinib hydrochloride An inhibitor of Abl and Src
  16. GC35753 CT-721
  17. GC35682 CHMFL-ABL/KIT-155
  18. GC35651 Cenisertib
  19. GC35462 Bafetinib A Bcr-Abl inhibitor
  20. GC40080 Bosutinib-d8 An internal standard for the quantification of bosutinib
  21. GC33368 BCR-ABL-IN-2
  22. GC33351 CZC-8004 (CZC-00008004) A tyrosine kinase inhibitor
  23. GC33343 BCR-ABL-IN-1
  24. GC33201 GZD856
  25. GC32867 Flumatinib (HHGV678) A Bcr-Abl inhibitor
  26. GC32703 Asciminib (ABL001) An allosteric inhibitor of Abl1
  27. GC10607 GNF-7 A multi-kinase inhibitor
  28. GC15884 Dasatinib Monohydrate An inhibitor of Abl and Src
  29. GC11140 Radotinib(IY-5511) A selective Bcr-Abl tyrosine kinase inhibitor
  30. GC10314 Imatinib (STI571) 伊马替尼 (STI571) (STI571) 是一种口服生物可利用的酪氨酸激酶抑制剂,可选择性抑制 BCR/ABL、v-Abl、PDGFR 和 c-kit 激酶活性。伊马替尼 (STI571) (STI571) 通过在 ATP 结合位点附近结合而起作用,将其锁定在封闭或自我抑制的构象中,从而半竞争性地抑制蛋白质的酶活性。伊马替尼 (STI571) 也是 SARS-CoV 和 MERS-CoV 的抑制剂。
  31. GC14007 DCC-2036 (Rebastinib) An orally bioavailable tyrosine kinase inhibitor
  32. GC10915 GZD824 A Bcr/Abl inhibitor
  33. GC13592 PD173955 A tyrosine kinase inhibitor
  34. GC13914 Flumatinib mesylate A Bcr-Abl inhibitor
  35. GC12779 PPY A PPY A 是一种有效的 T315I 突变体和野生型 Abl 激酶抑制剂,IC50 分别为 9 和 20 nM。 PPY A 抑制用野生型 Abl 和 Abl T315I 突变体转化的 Ba⁄F3 细胞,IC50 分别为 390 和 180 nM。 PPY A可用于慢性粒细胞白血病(CML)的研究。
  36. GC12637 PD 180970 An inhibitor of Bcr-Abl
  37. GC12172 1-Naphthyl PP1 Inhibitor of modified ‘analog-sensitive’ kinases
  38. GC15079 GNF 5 An allosteric inhibitor of Bcr-Abl
  39. GC10858 GNF 2 An allosteric inhibitor of Bcr-Abl
  40. GC15579 Adaphostin Adaphostin (NSC 680410) 是 AG957 的金刚烷基酯,是一种有效的 p210bcr/abl 抑制剂 (IC50=14 μM)。 Adaphostin 在人 T 淋巴细胞白血病细胞系中诱导细胞凋亡(IC50 范围为 17 至 216 nM)。 Adaphostin 对慢性和急性髓性白血病细胞具有显着的选择性活性。 Adaphostin 增加了 CLL B 细胞内的活性氧 (ROS) 水平。
  41. GC14075 Nocodazole A microtubule altering agent
  42. GC10970 WP1130 A deubiquitinase inhibitor
  43. GC14396 Ponatinib (AP24534) An inhibitor of native and mutant Bcr-Abl
  44. GC15197 Saracatinib (AZD0530) A dual inhibitor of c-Src and Abl
  45. GC11759 Imatinib Mesylate (STI571) An inhibitor of c-Abl, Bcr-Abl, PDGFR, and c-Kit
  46. GC13343 Bosutinib (SKI-606) An inhibitor of Src and Abl kinases
  47. GC14129 Nilotinib(AMN-107) A Bcr-Abl inhibitor
  48. GC13102 XL228 A tyrosine kinase inhibitor
  49. GC14237 Nilotinib monohydrochloride monohydrate A Bcr-Abl inhibitor
  50. GC10914 AST 487 A multi-kinase inhibitor
  51. GC14592 KW 2449 A multi-kinase inhibitor

Items 1 to 50 of 52 total

per page
  1. 1
  2. 2

Set Descending Direction